Culture Medium, Per Se Patents (Class 435/404)
-
Patent number: 8455246Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.Type: GrantFiled: May 8, 2009Date of Patent: June 4, 2013Assignee: Life Technologies CorporationInventors: Stephen Gorfien, Richard Fike, Glenn Godwin, Joyce Dzimian, David A. Epstein, Dale Gruber, Paul Price
-
Patent number: 8445282Abstract: A method is provided for culturing cochineal insects. In accordance with the method, a medium is created (101-109) from a mixture comprising a plant or cactus additive and a polymeric material. The medium is then inoculated (111) with a species selected from the group consisting of the genus Dactylopius.Type: GrantFiled: February 26, 2010Date of Patent: May 21, 2013Assignee: Badderloch Woad, Inc.Inventors: Denise Lynn Merkle, Connie M. Hendrickson
-
Publication number: 20130122543Abstract: The present application describes an optimized medium for growth of mammalian cells as well as polypeptide production. The cell culture medium is characterized by a Sow ratio of sodium to potassium ions, it further relates to the method of producing polypeptides using such cell culture media. Sn another aspect, the method of polypeptide production can also comprise a temperature shift and/or a pH-shift to further optimize growth and product yield.Type: ApplicationFiled: April 25, 2011Publication date: May 16, 2013Applicant: Novartis AGInventors: Christian Leist, Petra Meissner, Jörg Schmidt
-
Publication number: 20130122536Abstract: The present invention relates to: a method for producing an intermediate mesoderm cell from a human pluripotent stem cell, comprising a step of culturing the human pluripotent stem cell in a medium containing Activin A and Wnt or a functional equivalent of Wnt and a step of culturing cells in a medium containing BMP and Wnt or a functional equivalent of Wnt; to a method for producing a metanephric cell from the intermediate mesoderm cell produced by the first method; to a human pluripotent stem cell having a foreign reporter gene in the chromosome wherein the gene is expressed interlocked with the expression of endogenous OSR1; to a method for screening for an inducer for differentiation into intermediate mesoderm using the human pluripotent stem cell; and to a kit for inducing the differentiation into an intermediate mesoderm cell.Type: ApplicationFiled: July 21, 2011Publication date: May 16, 2013Applicant: KYOTO UNIVERSITYInventors: Kenji Osafune, Shin-ichi Mae, Masatoshi Kajiwara
-
Publication number: 20130109094Abstract: The present invention relates to nutritive medium, medium supplement, media subgroup and buffer formulations. The present invention provides powder nutritive medium, medium supplement and medium subgroup formulations, e.g., cell culture medium supplements (including powdered sera such as powdered fetal bovine serum (FBS)), medium subgroup formulations and cell culture media comprising all of the necessary nutritive factors that facilitate the in vitro cultivation of cells. The invention further provides powder buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent. The invention provides methods for production of media, media supplement, media subgroup and buffer formulations, and also provides kits and methods for cultivation of prokaryotic and eukaryotic cells, particularly bacterial cells, yeast cells, plant cells and animal cells (including human cells) using these dry powder nutritive media, media supplement, media subgroup and buffer formulations.Type: ApplicationFiled: September 13, 2012Publication date: May 2, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Richard M. Fike, William Whitford, Richard F. Hassett, Jeffrey W. Biddle, Laurel Biddle, Christine M. Biddle, Robert C. Radominski, Barbara M. Dadey
-
Patent number: 8431399Abstract: The present invention provides a method for restoring native chondrocyte phenotype and functions of, and/or increasing type II collagen as well as aggrecan mRNA expression levels and GAG accumulation level in dedifferentiated chondrocytes which have been subcultured and expanded in vitro, which comprising culturing the said dedifferentiated chondrocytes in vitro with a medium comprising type II collagen, or its biologically active peptide fragment(s) or analogs with or without growth factor(s), wherein the type II collagen or its biologically active peptide fragment(s) or analogs are effective to restore chondrocyte phenotype and functions of, and/or to increase type II collagen and aggrecan expression levels and GAG accumulation level in the said dedifferentiated chondrocytes.Type: GrantFiled: March 2, 2010Date of Patent: April 30, 2013Assignee: Taipei Medical UniversityInventors: Yu-Hui Tsai, Li-Hsuan Chiu, Chin-Chean Wong, Wen-Fu Lai, Shih-Ching Chen
-
Patent number: 8431398Abstract: Modulators of TRIM-NHL proteins and their use for modulating the proliferation and differentiation potential of stem cells and progenitor cells. Inhibitors of TRIM-NHL proteins, e.g. TRIM32, are useful for stem cell maintenance in vitro and in vivo. Assay methods for identifying TRIM-NHL protein modulators make use of the E3 ligase activity of TRIM32 or its interaction with Argonaute-1.Type: GrantFiled: September 19, 2008Date of Patent: April 30, 2013Assignee: IMBA-Institut fur Molekulare Biotechnologie GmbHInventors: Juergen Knoblich, Jens Schwamborn
-
Patent number: 8426202Abstract: The invention relates to nutrient media, in particular cell culture media, which contain at least one substance selected from the group comprising citric acid, succinic acid, malic acid, ?-keto-glutaric acid, fumaric acid, oxalacetic acid, isocitric acid, oxalosuccinic acid, tartaric acid, lactic acid, adipic acid and mixtures thereof and salts, derivatives or complexes of these acids. The invention further relates to the use and methods of production of said cell culture media, methods of cultivation of a cell culture in a cell culture medium according to the invention and cells that can be obtained by said methods.Type: GrantFiled: September 8, 2006Date of Patent: April 23, 2013Assignee: Cellca GmbHInventor: Aziz Cayli
-
Patent number: 8426203Abstract: Previous methods for culturing primate pluripotent stem cells have required either fibroblast feeder cells or a medium which was exposed to fibroblast feeder cells to maintain the stem cells in an undifferentiated state. It has now been found that high levels of fibroblast growth factor in a medium together with at least one of gamma aminobutyric acid, pipecolic acid, and lithium, enables pluripotent stem cells to remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. Without beta-mercaptoethanol, the medium improves cloning efficiency. Also, a matrix of human proteins can be used to culture the undifferentiated cells without exposing the cells to animal products. Further disclosed are new primate pluripotent cell lines made using the defined culture conditions, including the medium and the matrix. Such new cell lines will have never been exposed to animal cells, animal products, feeder cells or conditioned medium.Type: GrantFiled: March 22, 2012Date of Patent: April 23, 2013Assignee: Wisconsin Alumni Research FoundationInventors: James A. Thomson, Tenneille Ludwig
-
Patent number: 8426196Abstract: A method for regulating proliferation of cells, has steps of providing a first culture system with a surface that is coated with a biological material; inoculating and culturing cells on the surface of the first culture system in an appropriate medium, such that the proliferation of the cells is preserved; collecting the cells; providing a second culture system with a surface; and inoculating and culturing the cells on the surface of the second culture system in a culture medium containing the biological material, such that the proliferation of the cells is promoted. A method for regulating proliferation of cells is also provided, the method being the same as the previous method except that the step of inoculating and culturing in a first culture system is performed before the step of inoculating and culturing in a second culture system.Type: GrantFiled: June 5, 2008Date of Patent: April 23, 2013Inventor: Lynn L. H. Huang
-
Publication number: 20130089926Abstract: The present invention provides a method for differentiating human neural progenitor cells into dopaminergic neurons, comprising the step of culturing human neural progenitor cells in a medium containing fusaric acid. In addition, the present invention provides a medium for differentiation of human neural progenitor cells into dopaminergic neurons.Type: ApplicationFiled: June 7, 2011Publication date: April 11, 2013Applicant: College of Medicine Pochon Cha University Industry - Academic Cooperation FoundationInventor: Ji-Sook Moon
-
Patent number: 8415155Abstract: Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.Type: GrantFiled: October 19, 2010Date of Patent: April 9, 2013Assignee: Cellular Dynamics International, Inc.Inventors: Casey Stankewicz, Matt Riley, Nathaniel Beardsley, Wen Bo Wang, Peter Fuhrken, Steven Kattman
-
Patent number: 8415327Abstract: Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing cell death-related diseases or conditions in a human or a non-human animal.Type: GrantFiled: February 22, 2010Date of Patent: April 9, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Leonard A. Levin, Yun Luo
-
Patent number: 8415158Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.Type: GrantFiled: February 29, 2012Date of Patent: April 9, 2013Assignee: ViaCyte, Inc.Inventors: Allan J Robins, Thomas C Schulz
-
Publication number: 20130084640Abstract: The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production.Type: ApplicationFiled: September 4, 2012Publication date: April 4, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Paul PRICE, Stephen Gorfien, Douglas Danner, Mark Plavsic
-
Publication number: 20130065300Abstract: The present invention relates generally to nutritive medium, medium supplement, media subgroup and buffer formulations. Specifically, powdered nutritive medium, supplement, subgroup formulations, cell culture media comprising all of the necessary nutritive factors for in vitro cell cultivation, buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent are provided. Particularly, methods of production of these media, supplement, subgroup, buffer formulations and kits, and methods for the cultivation of prokaryotic and eukaryotic cells using these dry powdered nutritive media, supplement, subgroup and buffer formulations are provided. Methods of producing sterile, powdered media or supplement (e.g., powdered FBS, powdered transferrin, powdered insulin, powdered organ extracts, powdered growth factors), media subgroup and buffer formulations by gamma irradiation are provided.Type: ApplicationFiled: September 11, 2012Publication date: March 14, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Richard FIKE, William Whitford, William Biddle
-
Publication number: 20130059795Abstract: This invention describes a novel composition of matter describing a complex comprising leaf protein and a lipophilic substance(s), along with the method of producing it. Delivery of lipid-soluble materials into the body is challenging because they are generally highly insoluble in water and very subject to oxidative degradation. The inventors have found that leaf protein—the water-soluble proteins derived from plant leaves—can efficiently form a complex with lipophilic materials. This leaf protein—lipid-soluble material complex is an effective carrier of lipophilic substances. As such, the leaf protein—lipid-soluble material complex disclosed herein can be used for the delivery of lipophilic vitamins, fatty acids, caretenoids, lipophilic drugs, and other lipophilic materials. This complex can be used to deliver lipophiles in foods, nutritional and dietary supplements, topical compositions and in pharmaceutical products.Type: ApplicationFiled: March 7, 2011Publication date: March 7, 2013Inventors: Yangming Martin Lo, Ansu Elizabeth Cherian, Neil Allen Belson
-
Publication number: 20130058903Abstract: Provided herein are mesenchymal stem cells which have been modified by the introduction of polynucleotides encoding for a mammalian Cdk1 protein. These cells do not sense in culture and are non-tumorigenic thereby providing an ongoing source of cells as well as conditioned medium. The conditioned medium from these cells can be used for tissue repair. Also provided is a method of modifying mesenchymal stem cells which can be continuously propagated in culture and are non-tumorigenic.Type: ApplicationFiled: December 9, 2010Publication date: March 7, 2013Inventor: Techung Lee
-
Publication number: 20130040390Abstract: The present invention provides a chemically defined culture system, by which induced pluripotent stem (iPS) cells are obtained with high efficiency. The culture medium supplement of the present invention includes vitamin C and a glycogen synthase kinase-3 inhibitor; another culture medium supplement of the present invention further includes, in addition to vitamin C and the glycogen synthase kinase-3 inhibitor, vitamin B12, insulin, a receptor tyrosine kinase, and an anti-oxidant; and the culture medium supplement of the present invention may further be a mixture of the above two culture medium supplements with a serum replacement cell growth promoter. The present invention further provides a complete culture medium for iPS cells, which is formed by one or more of a basal culture medium, serum, and a serum replacement supplement, and the above culture medium supplements, or formed only by the above culture medium supplements and a basal culture medium.Type: ApplicationFiled: July 29, 2010Publication date: February 14, 2013Applicant: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCEInventors: Duanqing Pei, Jiekai Chen, Jing Liu
-
Patent number: 8372637Abstract: The present invention relates to a method of stabilizing a biological sample, having the steps of preparation of a biological sample, and of contacting the biological sample with a composition, having a substance according to the following structural formula: in which R1 is a hydrogen residue or a methyl residue, R2 and R3 are identical or different hydrocarbon residues with a length of the carbon chain of 1-20, and R4 is an oxygen, sulfur or selenium residue (FIG. 1).Type: GrantFiled: May 29, 2008Date of Patent: February 12, 2013Assignee: Qiagen, GmbHInventor: Vera Holländer
-
Patent number: 8372638Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.Type: GrantFiled: July 9, 2010Date of Patent: February 12, 2013Assignee: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Publication number: 20130034904Abstract: A culture medium is used for culturing neural cells. Each neural cell includes a neural cell body and at least one neurite branched from the neural cell body. The culture medium includes a substrate and a carbon nanotube structure located on the substrate. The carbon nanotube structure includes a number of carbon nanotube wires spaced apart from each other. A distance between adjacent carbon nanotube wires is greater than or equal to diameters of the neural cell bodies. The carbon nanotube wires are capable of guiding extending directions of the neurites.Type: ApplicationFiled: August 1, 2012Publication date: February 7, 2013Applicants: HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITYInventors: LI FAN, CHEN FENG, WEN-MEI ZHAO
-
Publication number: 20130034905Abstract: A method for making a culture medium for culturing neural cells is provided. Each neural cell includes a neural cell body and at least one neurite branched from the neural cell body. The method includes the following steps. An original carbon nanotube structure is provided. The original carbon nanotube structure includes at least one drawn carbon nanotube film including a number of carbon nanotubes joined end to end by van der Waals force. The carbon nanotubes are substantially oriented along a same direction. A carbon nanotube structure including a number of carbon nanotube wires spaced from each other is formed from the original carbon nanotube structure. A distance between adjacent carbon nanotube wires is larger than or equal to a diameter of the neural cell body, the carbon nanotube wires are capable of guiding extending directions of the neurites. The carbon nanotube structure is fixed on a substrate.Type: ApplicationFiled: August 1, 2012Publication date: February 7, 2013Applicants: HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITYInventors: CHEN FENG, LI FAN, WEN-MEI ZHAO
-
Patent number: 8367406Abstract: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.Type: GrantFiled: July 20, 2009Date of Patent: February 5, 2013Assignee: Celavie Biosciences, LLCInventor: Oleg V. Kopyov
-
Patent number: 8361797Abstract: The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells capable of producing the product in the medium.Type: GrantFiled: July 28, 2004Date of Patent: January 29, 2013Assignee: Medimmune LimitedInventors: Matthew David Osborne, Jonathan H. Dempsey
-
Patent number: 8361617Abstract: The present application provides a composition comprising porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffold described herein can be adjusted to mimic the gradient of densities found in natural tissue.Type: GrantFiled: July 15, 2010Date of Patent: January 29, 2013Assignees: Trustees of Tufts College, Massachusetts Institue of TechnologyInventors: David L. Kaplan, Rina Nazarov, Gordana Vunjak-Novakovic, Lorenz Meinel
-
Publication number: 20130004936Abstract: The present invention discloses a supercooling promoting agent comprising a tannin for producing practical water which does not freeze. As the tannin, a hydrolyzable tannin such as 2,3,6-tri-O-galloyl-?,?-D-hamamelose, 1,2,6-tri-O-galloyl-?-D-glucose, and a vitrification liquid, each of which contains the supercooling promoting agent are useful as a solution or the like for storing a biological material at low temperature.Type: ApplicationFiled: March 3, 2011Publication date: January 3, 2013Applicant: National University Corporation Hokkaido UniversitInventors: Seizo Fujikawa, Yukiharu Fukiharu, Keita Arakawa, Hiroshi Nishioka
-
Publication number: 20130004465Abstract: Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta.Type: ApplicationFiled: November 29, 2010Publication date: January 3, 2013Inventor: Zami Aberman
-
Publication number: 20130006384Abstract: A graft includes a carbon nanotube structure and a biological tissue. The carbon nanotube structure has a polar surface. The polar surface is formed by treating the carbon nanotube structure with polarization. The biological tissue is adhered on the polar surface. In addition, a method for manufacturing a graft is also provided.Type: ApplicationFiled: May 31, 2012Publication date: January 3, 2013Applicants: HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITYInventors: CHEN FENG, LI FAN, WEN-MEI ZHAO
-
Publication number: 20120329152Abstract: The present invention relates to methods of induction and isolation of progenitor cells from stem cell cultures, specifically liver progenitor cells from human embryonic stem cell cultures. In one embodiment, the present invention provides a method of inducing hepatocyte-like progenitor cells by placing a quantity of human embryonic stem cells in a medium supplemented with an inhibitor of the MAPK/MEK/ERK signaling pathway, FGFR, GSK3 and/or BMP.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Martin F. Pera, Tracy Zinberg, Kouichi Hasegawa
-
Patent number: 8338177Abstract: A method for culturing cells in the presence of an alcanoic acid for enhancing protein production.Type: GrantFiled: July 6, 2007Date of Patent: December 25, 2012Assignee: Lonza Biologics PLCInventors: David Mainwaring, Jeremy Wayte
-
Patent number: 8338175Abstract: The present disclosure describes a tissue system with conjunctival cells, including conjunctival stem cells. The conjunctival tissue system is derived from isolated tissue comprising conjunctival cells, and is suitable for restoring ocular surface impairments, particularly those that result from damaged or diseased conjunctiva. The tissue system is generated using a simple single medium culture scheme, and a support material, such as human amniotic membrane. The conjunctival tissue system generate is suitable for transplantation to treat the ocular surface of an eye of a subject that is damaged or diseased.Type: GrantFiled: February 23, 2007Date of Patent: December 25, 2012Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Kashyap Subhadra Devi, Kishore Reddy, Viraf Vasania
-
Publication number: 20120322152Abstract: The invention relates to methods of culturing and/or proliferating stem cells such as progenitor cells, multipotent and induced pluripotent stem (IPS) cells. More particularly, the invention relates to the use of macromolecular crowding created using carbohydrate-based macromolecule to promote the growth of the stem cells in an ex vivo culture, while preserving their multipotentiality.Type: ApplicationFiled: March 2, 2011Publication date: December 20, 2012Inventors: Michael Raghunath, Hui Li Loe, Anna Blocki
-
Publication number: 20120315343Abstract: A synchronized water is disclosed, in which all single water molecules at the same time are arranged in an identical way to a stable homogeneous microstructure, wherein said synchronized water in a distilled condition and at atmospheric pressure has a) a density of from 0.997855 to 0.998836 g/ml at 22° C., b) a water temperature at the freezing point of from ?6.7° C. to ?8.2° C., c) a melting point of from 0.1° C. to 0.2° C., d) a surface tension of from 72.3 to 72.7 dyn/cm at 22 and e) a dielectric constant of from 82.4 to 82.6 F/m, as well as a method for preparation thereof and different uses thereof.Type: ApplicationFiled: June 12, 2012Publication date: December 13, 2012Inventor: Benny JOHANSSON
-
Publication number: 20120315307Abstract: The present invention relates to a method of producing a hydrogel matrix comprising cartilage-forming cells wherein alginate, chitosan and cartilage-forming cells are mixed and subsequently polymerised into beads.Type: ApplicationFiled: February 11, 2011Publication date: December 13, 2012Inventors: Yves Henrotin, Christelle Sanchez, Frederic Kesteloot
-
Patent number: 8329466Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: GrantFiled: May 12, 2011Date of Patent: December 11, 2012Assignee: Bavarian Nordic A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 8329470Abstract: The invention relates to systems and methods for marketing and using products such as liquid materials, especially liquid reagents for use in microbiological and cellular biological laboratory settings include the use of unique color and simple numeric or alphanumeric identifiers to quickly and easily identify any product from a catalog list of products. Methods of marketing, advertising and producing such products are also disclosed. Particular embodiments include products, product packaging and product labeling. The invention also relates to collars and sleeves for containers, as well as related methods of use.Type: GrantFiled: August 1, 2006Date of Patent: December 11, 2012Assignee: Life Technologies CorporationInventors: Axel Unger, Elgin Meike Töpfer, Nicole Busch, Tom Hynek, Fredrik Johan Aidehag, Todd Pelman, Martin Naley
-
Publication number: 20120309056Abstract: The present invention relates to a glucose fed-batch process using concentrated cell culture for the efficient production of biologics, such as viral vaccines and recombinant proteins. In particular, the invention relates to culturing duck embryonic derived stem cells EB66 to obtain high yield of biological products from such cells.Type: ApplicationFiled: February 4, 2011Publication date: December 6, 2012Inventors: Arnaud Léon, Patrick Champion-Arnaud, Nicola Beltraminelli, Sylvana Bouletreau
-
Publication number: 20120301429Abstract: The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.Type: ApplicationFiled: May 25, 2012Publication date: November 29, 2012Inventors: Taymar E. HARTMAN, Paul W. Sauer, John E. Burky, Mark C. Wesson, Ping Y. Huang, Thomas J. Robinson, Braeden Partridge, J. Yun Tso
-
Publication number: 20120276631Abstract: The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose.Type: ApplicationFiled: April 26, 2012Publication date: November 1, 2012Applicant: Abbott LaboratoriesInventors: Cornelia T. Bengea, Lisa M. Rives
-
Publication number: 20120276630Abstract: The present invention relates generally to nutritive medium, medium supplement, media subgroup and buffer formulations. Specifically, powdered nutritive medium, supplement, subgroup formulations, cell culture media comprising all of the necessary nutritive factors for in vitro cell cultivation, buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent are provided. Particularly, methods of production of these media, supplement, subgroup, buffer formulations and kits, and methods for the cultivation of prokaryotic and eukaryotic cells using these dry powdered nutritive media, supplement, subgroup and buffer formulations are provided. Methods of producing sterile, powdered media or supplement (e.g., powdered FBS, powdered transferrin, powdered insulin, powdered organ extracts, powdered growth factors), media subgroup and buffer formulations by gamma irradiation are provided.Type: ApplicationFiled: April 20, 2012Publication date: November 1, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Richard FIKE, William Whitford, William Biddle
-
Patent number: 8298824Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.Type: GrantFiled: September 20, 2011Date of Patent: October 30, 2012Assignee: Sanofi Pasteur Vaxdesign CorporationInventors: William L. Warren, Heather Fahlenkamp, Russell G. Higbee, Eric M. Mishkin, Guzman Sanchez-Schmitz, Michael D. Rivard, Santosh Pawar
-
Publication number: 20120271041Abstract: The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc.Type: ApplicationFiled: November 19, 2010Publication date: October 25, 2012Inventor: Tanja Ficko Trcek
-
Publication number: 20120272349Abstract: The present invention provides a preparation method of a chimeric embryo and a chimeric rat, which is characterized by contacting a rat pluripotent stem cell and a host embryo in the presence of an ES cell differentiation inhibitor. The method includes (a) a step for contacting a fertilized host embryo collected from a female rat and a rat pluripotent stem cell in the presence of an ES cell differentiation suppressant, and (b) a step for culturing the host embryo in contact with the rat pluripotent stem cell to form a chimeric embryo.Type: ApplicationFiled: November 30, 2010Publication date: October 25, 2012Applicants: DS PHARMA BIOMEDICAL CO., LTD., NATIONAL CANCER CENTERInventors: Takahiro Ochiya, Masaki Kawamata
-
Publication number: 20120264190Abstract: Compositions comprising decellularized and delipidized extracellular matrix derived from adipose or loose connective tissue, and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, or damaged adipose or loose connective tissues or organs in a subject, preferably a human, and/or for tissue engineering, filing soft tissue defects, and cosmetic and reconstructive surgery, using a decellularized and delipidized adipose or loose connective tissue extracellular matrix of the invention are provided. Methods of preparing tissue culture surfaces and culturing cells with adsorbed decellularized and delipidized adipose or loose connective tissue extracellular matrix are also provided.Type: ApplicationFiled: June 6, 2012Publication date: October 18, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Karen L. Christman, D. Adam Young
-
Publication number: 20120264215Abstract: Disclosed are placenta-derived cell-conditioned culture media for stem cells. An animal-free, feeder-free method using the media is also provided for culturing stem cells. The media can prevent the stem cells from being contaminated with xenogeneic proteins or cells, and maintain human embryonic stem cells in an undifferentiated state for a long period of time in vitro with an economic benefit.Type: ApplicationFiled: March 15, 2012Publication date: October 18, 2012Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUDATION OF KOREA UNIVERSITYInventors: Byung Soo KIM, Seung-Jin LEE, Yong PARK, Ji Hye JUNG, Ji Hye KIM
-
Publication number: 20120258533Abstract: Disclosed herein are compositions and methods for a substantially protein-free media (PFM) optimized for cultivation of mammalian and/or avian cell-lines for manufacturing viral-based vaccines.Type: ApplicationFiled: April 6, 2012Publication date: October 11, 2012Applicant: CELLCURA ASAInventors: Lars Bredahl, Bent Nordbø
-
Publication number: 20120252119Abstract: The present invention relates to a method of producing an embryo from an oocyte by an assisted reproduction technology. The method includes (a) collecting an oocyte from an ovary of a subject in a collection medium comprising a first phosphodiesterase inhibitor and an agent that increases intracellular cAMP concentration in the oocyte, (b) culturing the oocyte in a maturation medium comprising a second phosphodiesterase inhibitor, and (c) producing an embryo from the oocyte by an assisted reproduction technology. The present invention also relates to methods of inducing oocyte maturation. For example a method of in vitro maturation of an oocyte is described which comprises steps (a) and (b) above. The present invention also relates to an oocyte maturation medium comprising a phosphodiesterase inhibitor and a ligand for inducing maturation of the oocyte. A combination product comprising an oocyte collection and maturation medium referred to above is also described.Type: ApplicationFiled: May 14, 2010Publication date: October 4, 2012Inventors: Robert Bruce Gilchrist, Jeremy Thompson, Firas Albuz
-
Publication number: 20120219632Abstract: We describe a method of monitoring the state of a cell, the method comprising establishing, for a selected microRNA (miRNA) species secreted by the cell, a ratio of: (a) a precursor form of the miRNA species (pre-miRNA); to (b) a mature form of the miRNA species (mature miRNA); in which the pre- to mature miRNA ratio so established is indicative of the state of the cell. We also describe a method comprising the steps of: (a) providing a mesenchymal stem cell (MSC); and (b) introducing an oncogene into the mesenchymal stem cell to thereby transform it; in which the transformed mesenchymal stem cell does not secrete a gene product of the oncogene into a medium in which it is grown.Type: ApplicationFiled: November 2, 2010Publication date: August 30, 2012Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Sai Kiang Lim
-
Patent number: 8252590Abstract: The present invention relates to mammalian cell culture media which comprise supernatant from some of the fractions of human plasma fractionation according to the Cohn method, more specifically, the supernatant of fractions I and II+III. When said supernatant is added as a culture medium supplement it provides various nutrients and factors for the effective maintenance and/or proliferation of the cultured mammalian cells. In addition, the present invention relates to the preparation process and use of said medium in the culture of mammalian cells.Type: GrantFiled: July 2, 2010Date of Patent: August 28, 2012Assignee: Grifols, S.A.Inventors: Juan Ignacio Jorquera Nieto, Montserrat Costa Rierola, José María Diez Cervantes